NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its earnings results on Wednesday, November, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

8 brokerages have issued twelve-month price objectives for Constellation Pharmaceuticals' shares. Their forecasts range from $40.00 to $65.00. On average, they expect Constellation Pharmaceuticals' share price to reach $49.14 in the next twelve months. This suggests a possible upside of 41.4% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Headlines about CNST stock have been trending extremely negative recently, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 1,570,000 shares, a drop of 6.0% from the January 30th total of 1,670,000 shares. Based on an average daily volume of 596,900 shares, the days-to-cover ratio is presently 2.6 days. Approximately 11.2% of the shares of the stock are sold short. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include Reata Pharmaceuticals (RETA), Amarin (AMRN), United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM) and Zai Lab (ZLAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Axsome Therapeutics (AXSM), Canopy Growth (CGC), Sorrento Therapeutics (SRNE), AT&T (T), Arrowhead Pharmaceuticals (ARWR), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), Viking Therapeutics (VKTX) and NIO (NIO).

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (6.88%), Regents of The University of California (4.26%), FMR LLC (3.86%), Casdin Capital LLC (2.96%), Point72 Asset Management L.P. (1.22%) and State Street Corp (0.67%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Karen Valentine, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Casdin Capital LLC, P.A.W. Capital Corp, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc. and Bank of America Corp DE. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Of The University Of C Regents and Patrick Trojer. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was bought by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, Point72 Asset Management L.P., FMR LLC, Franklin Resources Inc., Jennison Associates LLC, Candriam Luxembourg S.C.A., Geode Capital Management LLC and Cadian Capital Management LP. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $34.76.

Constellation Pharmaceuticals has a market capitalization of $1.43 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]